3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Advanced Cancer
3
Uveal Melanoma
2
Recurrence
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Various Advanced Cancer
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
Cyclophosphamide
216
Methotrexate
140
Cytarabine
131
Vincristine
110
fludarabine phosphate
103
Peripheral Blood Stem Cell Transplantation
98
Filgrastim
92
Etoposide
92
Dexamethasone
89
Mycophenolic Acid
71
Doxorubicin
70
Whole-Body Irradiation
67
Mercaptopurine
66
Busulfan
65
Tacrolimus
64
Radiotherapy
63
Cyclosporine
62
Prednisone
55
Daunorubicin
53
pegaspargase
51
Asparaginase
51
Rituximab
48
fludarabine
47
Granulocyte Colony-Stimulating Factor
46
Melphalan
45
Antilymphocyte Serum
43
Clofarabine
42
Calcium Dobesilate
38
Methylprednisolone
36
Leucovorin
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled